For the past 50 years, transurethral resection of the prostate (TURP) has been the most common surgical treatment for benign prostattic hyperplasia (BPH). Alternative methods for treating BPH have been established during the past 10 years.We assessed the safety and efficacy of visual laser ablation of the prostate (VLAP), performed with the Urolase and ProLase II laser fiber, compared to TURP in patients with BPH.In this non-randomized comparative study, 50 BPH patients were treated with TURP and 50 and 25 were conducted with VLAP using Urolase and ProLase II laser fibers. Efficacy was assessed with International Prostate symptom score, urinary flow rate, postvoid residural urinary volume and estimated prostate volume.There was a clinically significant improvement in all efficacy parameters in all groups. In the TURP, Urolase and ProLase II groups 81.6% (40/49), 92.0% (46/50) and 84.0% (21/25) were categorized as effective cases at 3 months postoperatively, and 100.0% (16/16), 93.1% (27/29) and 84.6% (11/13) were showed effective cases at 12 months postoperatively. Total and postoperative hospitalization in VLAP group were shorter but duration of the postoperative balloon catheter was longer than conventional TURP group.Although TURP remains standard surgical treatment for BPH, VLAP is attended with less morbidity and made a similar clinical effect compared to TURP. VLAP in conjunction with TURP may result in less risk of postoperative urinary retention and vesical irritability.